← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Radix Pharmaceuticals, Inc.
Potomac, MD
$4,433,825
Total funding
7
Grants
Funding over time
peak $941.2K · FY2005–13$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$4,433,825 · 7
By mechanism
R44$2,843,317 · 3
R43$1,590,508 · 4
Investigators at Radix Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Development of Small Molecules as Antiprotozoal Agents$749,856
R44 · FY2013 · AI
Preclinical Studies of Natural Product Derivatives as Antimalarial Agents$547,433
R44 · FY2011 · AI
Development of Small Molecules as Antiprotozoal Agents$490,480
R44 · FY2012 · AI
Preclinical Studies of Natural Product Derivatives as Antimalarial Agents$450,748
R44 · FY2012 · AI
Pre-Clinical Development of Natural Product Analogues as Antimalarial Agents$304,920
R44 · FY2007 · AI
Pre-Clinical Evaluation of Antimalarial Natural Products from Carica papaya L.$300,000
R43 · FY2008 · AI
Isolation and Antimalarial Activity of Small Molecules from Ocimum sanctum$300,000
R43 · FY2009 · AI
Isolation and Antimalarial Activity of Small Molecules from Ocimum sanctum$300,000
R43 · FY2008 · AI
Pre-Clinical Development of Natural Product Analogues as Antimalarial Agents$299,880
R44 · FY2006 · AI
Development of Natural Product as Antimalarial Agent$299,880
R43 · FY2007 · AI
Pre-Clinical Evaluation of Antimalarial Natural Products from Carica papaya L.$290,628
R43 · FY2009 · AI
Synthesis and Evaluation of Novel Antimalarial Agents$100,000
R43 · FY2005 · AI